Home » Topics » BioWorld Science

BioWorld Science
RSS

CStone initiates phase I trial in Australia with MEK inhibitor CS-3006

June 20, 2018

ACY-1215 in combination with nab-paclitaxel shows promising activity in metastatic breast cancer

June 20, 2018

Sarepta reports preliminary data from phase I/IIa gene therapy trial in Duchenne muscular dystrophy

June 20, 2018

IDMC recommends continuation of phase III study of masitinib for metastatic CRPC

June 20, 2018

Argenx reports cohort 1 interim data from phase II study of efgartigimod in pemphigus vulgaris

June 20, 2018

Clinical benefit noted with NIR-178 in patients with non-small cell lung cancer

June 20, 2018

Tumor mutations can aid variant calling for germline

June 20, 2018

Idorsia initiates phase III study of aprocitentan for resistant hypertension

June 20, 2018

Kala updates registration plan for KPI-121 for short-term treatment of dry eye disease

June 20, 2018

Can-Fite updates status of phase II trial of namodenoson in advanced HCC

June 20, 2018

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...